Floatz Rating
C35/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
20Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04552288CT.gov Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Benralizumab (this asset) | Memorial Sloan Kettering Cancer Center | P2 | C · 35 |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P1/2 | B |
| Tipiracil | Academic and Community Cancer Research United | P2 | CCC |
| Trifluridine | Academic and Community Cancer Research United | P2 | CCC |
| Palbociclib | Academic and Community Cancer Research United | P2 | CCC |
| Nivolumab | Asan Medical Center | P1/2 | CCC |
| Binimetinib | Academic and Community Cancer Research United | P2 | CCC |
| Eflornithine | Aminex Therapeutics, Inc. | P1/2 | CCC |
| Cyclophosphamide | Imugene Limited | P1 | CCC |
+42 more in the Carcinoma cohort
Other indications for Benralizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bullous Pemphigoid | — | P3 | C · 37 |
| Bronchiectasis | — | P3 | C · 37 |
| Hematopoietic And Lymphoid Cell Neoplasm | — | P2 | C · 33 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Benralizumab in Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/benralizumab-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →